No Data
No Data
Leerink Partners Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $7
Eledon Pharmaceuticals: A Strong Buy on Robust Financials and Promising Clinical Trials
Express News | Eledon Pharmaceuticals Inc - Disclosure Controls & Procedures Were Not Effective as of June 30, 2023, Sept 31, 2023, Dec 31, 2023 & March 31, 2024
Express News | Eledon Pharmaceuticals Inc - Internal Control Over Financial Reporting Was Not Effective as of Dec 31, 2023
Express News | Eledon Pharmaceuticals- Identified Material Weakness in Internal Control Over Financial Reporting Related to Accounting for Equity Instruments
Express News | Eledon Pharmaceuticals Inc: Expects Sufficient Liquidity Through December 2025
No Data